GNLX: סך החוב של החברה Genelux Corp

Genelux Corporation (GNLX) is developing advanced tumor-fighting methods utilizing viral therapy. Serving as an assessment tool, this debt value chart confirms that this metric stands at 0.00. The Olvi-Vec technology enables targeted treatment of ovarian cancer, providing aid to critically ill patients. However, the company faces a liquidity shortage and the depletion of reserves due to costly testing in the absence of regular profits.

Stress testing assets requires strict control over debt load. Genelux Corporation (GNLX) is investing in the development of the Olvi-Vec platform for ovarian cancer therapy. This metric aggregates all external borrowings to determine the issuer's overall financial stability. By analyzing the current level of liabilities, an investor assesses the risk of credit dependency in the absence of operating profit. Comparing debt with expansion rates confirms the viability of the business model.